| Literature DB >> 33223766 |
Muhamad Sahlan1, Rafidha Irdiani1, Darin Flamandita1, Reza Aditama2, Saleh Alfarraj3, Mohammad Javed Ansari4, Apriliana Cahya Khayrani1, Diah Kartika Pratami5, Kenny Lischer1.
Abstract
Coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health concern, as the World Health Organization declared this outbreak to be a global pandemic in March 2020. The need for an effective treatment is urgent because the development of an effective vaccine may take years given the complexity of the virus and its rapid mutation. One promising treatment target for COVID-19 is SARS-CoV-2 main protease. Thus, this study was aimed to examine whether Sulawesi propolis compounds produced by Tetragonula sapiens inhibit the enzymatic activity of SARS-CoV-2 main protease. In this study, molecular docking was performed to analyze the interaction profiles of propolis compounds with SARS-CoV-2 main protease. The results illustrated that two compounds, namely glyasperin A and broussoflavonol F, are potential drug candidates for COVID-19 based on their binding affinity of -7.8 kcal/mol and their ability to interact with His41 and Cys145 as catalytic sites. Both compounds also displayed favorable interaction profiles with SARS-CoV-2 main protease with binding similarities compared to inhibitor 13b as positive control 63% and 75% respectively.Entities:
Keywords: COVID-19; Molecular docking; Potent inhibitor; SARS-CoV-2 main protease; Sulawesi propolis
Year: 2020 PMID: 33223766 PMCID: PMC7670966 DOI: 10.1016/j.jksus.2020.101234
Source DB: PubMed Journal: J King Saud Univ Sci ISSN: 1018-3647
Identified Sulawesi propolis compounds.
| No | Compound | Molecular Formula | 2-Dimensional Structure | References |
|---|---|---|---|---|
| 1 | α-Tocopherol succinate | C32H52O5 | ( | |
| 2 | Xanthoxyletin | C15H14O4 | ( | |
| 3 | P-Coumaric acid | C9H10O3 | ( | |
| 4 | Curcumene | C15H22 | ( | |
| 5 | Thymol | C10H14O | ( | |
| 6 | Tetralin | C10H12 | ( | |
| 7 | Deoxypodophyllotoxin | C22H22O7 | ( | |
| 8 | Sulabiroins A | C22H22O7 | ( | |
| 9 | Sulabiroins B | C23H26O7 | ( | |
| 10 | 2′,3′-Dihydro-3′-hydroxypapuanic acid | C25H38O7 | ( | |
| 11 | (–)-Papuanic acid | C25H36O6 | ( | |
| 12 | (–)-Isocalolongic Acid | C24H34O6 | ( | |
| 13 | Isopapuanic acid | C25H36O6 | ( | |
| 14 | Isocalopolyanic acid | C24H32O6 | ( | |
| 15 | Glyasperin A | C25H26O7 | ( | |
| 16 | Broussoflavonol F | C25H26O7 | ( | |
| 17 | (2S)-5,7-Dihydroxy-4′-methoxy-8-prenylflavanone | C20H20O5 | ( | |
| 18 | Isorhamnetin | C16H12O7 | ( | |
| 19 | (1′S)-2-Trans,4- | C15H20O4 | ( | |
| 20 | (1′S)-2-Cis,4- | C15H20O4 | ( |
Fig. 1Structure of inhibitor 13b and 14b (Zhang et al., 2020).
Lipinski’s RO5 selection.
| No. | Compounds | Molecular weight (g/mol) | Log P | Number of H-bond acceptor | Number of H-bond donor | Number of violations |
|---|---|---|---|---|---|---|
| 1 | Sulabiroins A | 398.411 | 2.74 | 7 | 0 | 0 |
| 2 | Sulabiroins B | 414.454 | 2.55 | 7 | 0 | 0 |
| 3 | 2',3'-Dihydro-3'-hydroxypapuanic acid | 450.572 | 4.33 | 7 | 3 | 0 |
| 4 | (−)-Papuanic acid | 432.557 | 5.57 | 6 | 2 | 1 |
| 5 | (−)-Isocalolongic acid | 404.503 | 4.78 | 6 | 2 | 0 |
| 6 | Isopapuanic acid | 432.557 | 5.57 | 6 | 2 | 1 |
| 7 | Isocalopolyanic acid | 416.514 | 5.03 | 6 | 2 | 1 |
| 8 | Glyasperin A | 438.476 | 4.84 | 7 | 5 | 0 |
| 9 | Broussoflavonol F | 438.476 | 4.84 | 7 | 5 | 0 |
| 10 | (2s)-5,7-Dihydroxy-4'-methoxy-8-prenylflavanone | 340.375 | 4.19 | 5 | 3 | 0 |
| 11 | Isorhamnetin | 316.265 | 1.78 | 7 | 4 | 0 |
| 12 | (1's)-2-Trans,4 trans-abscisic acid | 264.321 | 2.08 | 4 | 2 | 0 |
| 13 | (1's)-2-Cis,4 trans-abscisic acid | 264.321 | 2.08 | 4 | 2 | 0 |
| 14 | α-tocopherol succinate | 530.790 | 9.18 | 4 | 1 | 2 |
| 15 | Xanthoxyletin | 258.273 | 2.01 | 3 | 0 | 0 |
| 16 | P-coumaric acid | 164.160 | 2.12 | 3 | 2 | 0 |
| 17 | Curcumene | 202.341 | 5.19 | 0 | 0 | 1 |
| 18 | Thymol | 150.221 | 3.42 | 1 | 1 | 0 |
| 19 | Tetralin | 132.206 | 3.27 | 0 | 0 | 0 |
| 20 | Deoxypodophyllotoxin | 398.411 | 2.63 | 6 | 0 | 0 |
Docking score between main protease and test compounds.
| No | Compounds | Docking score (kcal/mol) |
|---|---|---|
| 1 | * Inhibitor 13b | −8.2 |
| 2 | 14b | −7.2 |
| 3 | Broussoflavonol F | −7.8 |
| 4 | Glyasperin A | −7.8 |
| 5 | Sulabiroins A | −7.6 |
| 6 | Isorhamnetin | −7.5 |
| 7 | Deoxypodophyllotoxin | −7.3 |
| 8 | (2S)-5,7-Dihydroxy-4′-methoxy-8-prenylflavanone | −7.1 |
| 9 | Sulabiroins B | −7.0 |
| 10 | Isocalopolyanic acid | −6.8 |
| 11 | Isopapuanic acid | −6.8 |
| 12 | 2′,3′-Dihydro-3′-hydroxypapuanic acid | −6.7 |
| 13 | (−)-Isocalolongic acid | −6.7 |
| 14 | (−)-Papuanic acid | −6.6 |
| 15 | Xanthoxyletin | −6.2 |
| 16 | (1′S)-2-Trans-4-trans-abscisic acid | −6.1 |
| 17 | (1′S)-2-Cis-4-trans-abscisic acid | −5.9 |
| 18 | α-Tocopherol succinate | −5.1 |
| 19 | P-Coumaric acid | −4.9 |
| 20 | Curcumene | −4.7 |
| 21 | Thymol | −4.7 |
| 22 | Tetralin | −4.4 |
*) Native ligand as a control.
Fig. 2Visualization of the molecular interactions of main protease with various ligands. (a) 13b, (b) 14b, (c) broussoflavonol F, (d) glyasperin A, (e) sulabiroins A. The purple lines denote the ligand structure, whereas the brown lines denote the structure of amino acid residues. The molecular interactions are reflected as dashed lines and arcs. The green dashed lines between atoms represent hydrogen bonds, and the numbers above these lines indicate the length of the bond. Meanwhile, the arcs with spokes radiating toward the ligand atoms represent hydrophobic interactions. The atoms involve in hydrophobic interactions are indicated by the presence of spokes radiating back (Wallace et al., 1995).
Interaction profiles between main protease and test compounds
| No. | Compounds | Hydrogen bonds | Hydrophobic interactions | Number of interactions | Binding similarity |
|---|---|---|---|---|---|
| 1 | * 13b | His41, Gly143, Ser144, Cys145, Glu166 | Thr25, Cys44, Met49, Leu141, Asn142, His163, His164, Met165, Leu167, Asp187, Gln189 | 16 | 100% |
| 2 | 14b | Phe140, Glu166 | His41, Met49, Leu141, Asn142, His163, His164, Met165, Leu167, Pro168, Asp187, Arg188, Gln189 | 14 | 71% |
| 3 | Broussoflavonol F | Gly143, Ser144, Cys145 | Thr26, His41, Met49, Leu141, Asn142, His163, His164, Met165, Glu166, Arg188, Gln189 | 14 | 75% |
| 4 | Glyasperin A | Thr25, His164, Arg188 | His41, Cys145, Met165, Glu166, Val186, Asp187, Gln189, Thr190, Gln192 | 13 | 63% |
| 5 | Sulabiroins A | Glu166 | His41, Asn142, His164, Met165, Asp187, Arg188, Gln189 | 8 | 44% |
*) Native ligand as a control.
Hydrogen bonds between main protease and test compounds
| No. | Compounds | Hydrogen bond distance (Å) | Interacting amino acid | Binding ligand group | Binding amino acid group |
|---|---|---|---|---|---|
| 1 | * 13b | 2,80 | Glu166 | –NH | –O |
| 2,86 | Ser144 | –NH | –OH | ||
| 3,03 | His41 | –O | –NH | ||
| 3,12 | Gly143 | –O | –NH2 | ||
| 3,15 | Ser144 | –O | –NH2 | ||
| 3,20 | Gly143 | –O | –NH2 | ||
| 3,27 | Cys145 | –O | –NH2 | ||
| 3,30 | Glu166 | –O | –NH2 | ||
| 3,32 | Cys145 | –O | –SH | ||
| 2 | 14b | 3.02 | Phe140 | –NH2 | –O |
| 3.20 | Glu166 | –O | –NH2 | ||
| 3 | Broussoflavonol F | 2.94 | Ser144 | –OH | –O |
| 2.97 | Ser144 | –OH | –NH2 | ||
| 3.01 | Gly143 | –OH | –NH2 | ||
| 3.27 | Cys145 | –OH | –NH2 | ||
| 4 | Glyasperin A | 2.73 | Thr25 | –OH | –OH |
| 2.73 | Arg188 | –OH | –OH | ||
| 2.99 | His164 | –OH | –O | ||
| 3.01 | Arg188 | –OH | –NH2 | ||
| 5 | Sulabiroins A | 3.06 | Glu166 | –O | –NH2 |
*) Native ligand as a control.